Results 51 to 60 of about 97,767 (354)

Destiny Diaz in a Senior Instrumental Recital

, 2023
This is the program for the senior flute recital of Destiny Diaz held on April 14, 2023, in the McBeth Recital ...
Diaz, Destiny
core  

Not liberation but justice: An Analysis of Reinhold Niebuhr's understanding of human destiny in the light of the Doctrine of the Atonement. [PDF]

, 1992
Doctor Theologiae - DThThis thesis takes a new approach to the interpretation of Reinhold Niebuhr's thought by arguing that the category of "redemption" is a key hermeneutical concept for understanding his theology.
de Gruchy, Stephen Mark
core   +1 more source

Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial

Nature Medicine
Trastuzumab deruxtecan (T-DXd) demonstrated significantly improved efficacy over trastuzumab emtansine (T-DM1) in DESTINY-Breast03 (median follow-up, 28 months). We report updated efficacy and safety analyses, including secondary and exploratory efficacy
J. Cortés, S. Hurvitz, Seock-Ah Im, H. Iwata, G. Curigliano, Sung-Bae Kim, Joanne W. Y. Chiu, J. Pedrini, Wei Li, K. Yonemori, G. Bianchini, S. Loi, G. Borges, Xian Wang, T. Bachelot, Shunsuke Nakatani, S. Ashfaque, Zhengkang Liang, A. Egorov, E. Hamilton   +19 more
semanticscholar   +1 more source

Development of Registry Data to Create Interactive Doctor-Patient Platforms for Personalized Patient Care, Taking the Example of the DESTINY System

Frontiers in Digital Health, 2021
“Real-world evidence (RWE)” is becoming increasingly important in order to integrate the results of randomized studies into everyday clinical practice. The data collection of RWE is usually derived from large-scale national and international registries ...
A. Bergmann, M. Stangel, M. Weih, P. Hövell, S. Braune, Monika Köchling, Fabian Roßnagel   +6 more
semanticscholar   +1 more source

Figments of Imagination v. 29 (2021): 26

, 2021
Art "Cooll wanderlust" by Destiny ...

core  

Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial

Nature Medicine
Trastuzumab deruxtecan (T-DXd) showed statistically significant clinical improvement in patients with human epidermal growth factor receptor 2-positive (HER2+) gastric cancer in the DESTINY-Gastric01 trial.
K. Shitara, Yung-Jue Bang, S. Iwasa, N. Sugimoto, M. Ryu, D. Sakai, Hyun Cheol Chung, H. Kawakami, H. Yabusaki, Yasuhiro Sakamoto, T. Nishina, K. Inaki, Y. Kuwahara, Naoya Wada, F. Suto, Takeo Arita, M. Sugihara, Zenta Tsuchihashi, K. Saito, A. Kojima, K. Yamaguchi   +20 more
semanticscholar   +1 more source

Understanding the dynamic and destiny of memories

Neuroscience and Biobehavioral Reviews, 2021
Memory formation enables the retention of life experiences overtime. Based on previously acquired information, organisms can anticipate future events and adjust their behaviors to maximize survival.
L. de Oliveira Alvares, F. H. Do-Monte
semanticscholar   +1 more source

Diversity and complexity in neural organoids

FEBS Letters, EarlyView.
Neural organoid research aims to expand genetic diversity on one side and increase tissue complexity on the other. Chimeroids integrate multiple donor genomes within single organoids. Self‐organising multi‐identity organoids, exogenous cell seeding, or enforced assembly of region‐specific organoids contribute to tissue complexity.
Ilaria Chiaradia, Madeline A. Lancaster
wiley   +1 more source

Epigenetic blind spots – the role of DNA methylation dynamics in stem cell‐based models of embryogenesis

FEBS Letters, EarlyView.
Embryo‐like structures (stembryos) are an innovative tool, but they are hindered by experimental variability and limited developmental potential. DNA methylation is crucial for mammalian development, but its status in stembryo models is poorly characterized.
Sara Canil, Anna Corrà, Annalisa Scapolatiello, Chengxiang Qiu, Gianluca Amadei   +4 more
wiley   +1 more source

De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial.

The Lancet Haematology, 2019
BACKGROUND All studies of treatment-free remission (TFR) in patients with chronic myeloid leukaemia have discontinued tyrosine kinase inhibitor (TKI) treatment abruptly and have focussed on patients with stable MR4 (BCR-ABL to ABL ratio ≤0·01%). We aimed
R. Clark, F. Polydoros, J. Apperley, D. Milojkovic, K. Rothwell, C. Pocock, J. Byrne, H. de Lavallade, W. Osborne, L. Robinson, S. O’Brien, Lucy Read, L. Foroni, M. Copland   +13 more
semanticscholar   +1 more source